Does Medicare Cover GLP-1 Medications?
Starting July 1, 2026, Medicare is covering Wegovy and Zepbound for weight loss for the first time, through a program called the Medicare GLP-1 Bridge. The copay is $50 per month, flat, for eligible Part D enrollees. This runs through December 31, 2027. Ozempic and Mounjaro remain covered under standard Part D for type 2 diabetes, as they have been.
Reviewed by GlobalGLP1 Editorial Team • Updated May 2026 • Sources: publicly available coverage data
Medication Coverage
| Medication | Status | Tier | Notes |
|---|---|---|---|
| Ozempic (semaglutide) | Covered | Part D Formulary | Covered for type 2 diabetes under Medicare Part D. Not covered for weight loss under the bridge program. If you want semaglutide for weight loss, ask for Wegovy. |
| Wegovy (semaglutide) | Covered | GLP-1 Bridge ($50/mo) | Covered for weight loss starting July 1, 2026 via the Medicare GLP-1 Bridge at a flat $50/month copay. Requires prior authorization and BMI eligibility. Copay does not count toward your Part D deductible or annual out-of-pocket cap. |
| Mounjaro (tirzepatide) | Covered | Part D Formulary | Covered for type 2 diabetes under standard Part D. Not covered for weight loss under the bridge program. For weight-management tirzepatide coverage, ask for Zepbound. |
| Zepbound (tirzepatide) | Covered | GLP-1 Bridge ($50/mo) | Covered for weight loss starting July 1, 2026 via the Medicare GLP-1 Bridge (KwikPen formulation) at a flat $50/month copay. Same eligibility rules and copay structure as Wegovy under the bridge. |
| Foundayo | Covered | GLP-1 Bridge ($50/mo) | New Novo Nordisk weight-loss medication covered under the bridge program starting July 1, 2026. Available as a daily pill. |
| Saxenda (liraglutide) | Varies | Part D (limited) | Limited coverage on most Part D plans. Not included in the GLP-1 Bridge. Largely being replaced by newer medications. |
| Compounded semaglutide | Not Covered | N/A | Medicare does not cover compounded medications, including compounded semaglutide or tirzepatide. |
Prior Authorization
Prior authorization is required for all GLP-1 Bridge medications. Your prescribing provider submits the authorization request to your Part D plan on your behalf, attesting that you meet the BMI criteria and that the prescription is for weight reduction. Part D plans must respond within 72 hours for standard requests and 24 hours for urgent ones. Not every Part D plan is participating in the bridge, so confirm your plan is enrolled before scheduling your appointment.
Cost Estimates
Savings tip: The GLP-1 Bridge $50 copay does not count toward your Part D deductible or the $2,100 annual out-of-pocket cap, and it is not reduced by the Extra Help (Low Income Subsidy). For diabetes GLP-1s (Ozempic, Mounjaro) on standard Part D, the $2,100 annual cap does apply. Manufacturer savings cards cannot be used with any Medicare coverage.
Requirements for Coverage
- Active Medicare Part D enrollment (standalone PDP or Medicare Advantage with Part D)
- BMI 35 or higher automatically qualifies for the bridge program
- BMI 27 or higher with: pre-diabetes, previous heart attack, previous stroke, or symptomatic peripheral artery disease
- BMI 30 or higher with: heart failure with preserved ejection fraction, uncontrolled hypertension, or chronic kidney disease stage 3a+
- Prior authorization submitted by your prescribing provider
- Prescription must be specifically for weight reduction (not for diabetes or cardiovascular indications)
- Your prescriber must be enrolled in Medicare
Tips for Getting Approved
Schedule your appointment in May or June. Prior authorization takes time, and you want coverage from July 1, not a month after.
Confirm your Part D plan participates in the bridge before booking. Plan participation is voluntary. Call the number on your insurance card to ask.
Ask for Wegovy or Zepbound by name. Asking for Ozempic or Mounjaro for weight loss will result in a denial. The bridge covers the weight-management-approved products only.
Bring BMI documentation and any qualifying diagnosis records to your appointment. Your provider needs these for the prior authorization.
Low-income subsidy (Extra Help) recipients pay the full $50 copay under the bridge. The LIS discount does not apply to bridge program drugs.
The bridge runs through December 2027. After that, coverage may continue under the BALANCE model, but that is not guaranteed. Ask your plan about 2028 options closer to year-end 2027.
Approval Statistics
The GLP-1 Bridge has clearer eligibility criteria than prior weight-management coverage attempts, which should improve approval rates. Denials are most common when BMI documentation is missing or the prescription is coded for the wrong indication (diabetes vs. weight loss).
Common Denial Reasons & How to Avoid Them
How to avoid: Your provider needs a current BMI measurement in your chart and any qualifying diagnoses documented with the right codes. Bring your most recent lab results and get your BMI measured at the appointment.
How to avoid: The bridge only covers GLP-1s prescribed specifically for weight reduction. Make sure your provider codes the prior auth as an obesity or weight-management indication, not as a diabetes or cardiovascular treatment.
How to avoid: Not all Part D plans have enrolled in the bridge program. If your plan is not participating, your option is to switch plans during the next open enrollment period (October 15 through December 7), or call your plan to ask if they plan to join.
How to avoid: Ozempic and Mounjaro are not covered under the bridge. Only Wegovy, Zepbound, and Foundayo are. If your authorization was submitted for Ozempic for weight loss, resubmit it as Wegovy.
Step Therapy Requirements
Metformin is the standard first-line treatment. Most Part D plans require documented blood sugar (A1C) above 7% despite metformin before approving a GLP-1. Some plans may also require trying a sulfonylurea.
No step therapy requirement under the bridge program. You do not need to prove you tried other weight-loss medications first. Your provider documents that you meet the BMI and clinical criteria, and submits the prior authorization.
Frequently Asked Questions
Yes. Medicare Part D covers Ozempic and Mounjaro for type 2 diabetes with prior authorization. Starting July 1, 2026, the Medicare GLP-1 Bridge program covers Wegovy, Zepbound, and Foundayo for weight loss at a flat $50/month copay through December 31, 2027. Bridge eligibility requires BMI 35+ or BMI 27+ with pre-diabetes, prior heart attack, prior stroke, or peripheral artery disease. Compounded semaglutide is not covered. Manufacturer savings cards cannot be used with any Medicare coverage.
Medicare covers Ozempic (semaglutide) under Part D for type 2 diabetes, Mounjaro (tirzepatide) under Part D for type 2 diabetes, Wegovy (semaglutide) under the GLP-1 Bridge at $50/month for weight loss starting July 1, 2026, Zepbound (tirzepatide KwikPen) under the Bridge at $50/month, and Foundayo (new Novo Nordisk weight-loss pill) also under the Bridge. Saxenda has limited Part D coverage on most plans. Compounded semaglutide is not covered. Note that not every Part D plan is participating in the Bridge, so confirm your plan is enrolled.
Yes, starting July 1, 2026. Medicare covers Wegovy for weight loss through the GLP-1 Bridge program at a flat $50 per month copay. You need Medicare Part D enrollment and BMI eligibility: BMI 35+ automatically qualifies, or BMI 27+ with pre-diabetes, a prior heart attack or stroke, or peripheral artery disease.
No. Ozempic is covered by Medicare Part D for type 2 diabetes, but not for weight loss. The GLP-1 Bridge covers weight-management-approved products: Wegovy, Zepbound, and Foundayo. If you want semaglutide for weight loss and have Medicare, ask your doctor about Wegovy.
The Medicare GLP-1 Bridge is a CMS demonstration program that covers Wegovy, Zepbound, and Foundayo for weight loss at a $50/month copay. It runs July 1, 2026 through December 31, 2027. It was created to expand access to weight-loss medications while permanent legislative coverage works through Congress.
Under the GLP-1 Bridge, the copay is $50 per month flat, regardless of dosage. Note that this $50 does not count toward your Part D deductible or the annual $2,100 out-of-pocket cap. Without the bridge, Wegovy runs $1,000 to $1,300 per month at retail.
Yes, starting July 1, 2026 via the GLP-1 Bridge. The KwikPen formulation of Zepbound is covered at $50/month. Eligibility requirements are the same as for Wegovy: BMI 35+ or BMI 27+ with a qualifying condition.
No. Federal law prohibits manufacturer savings cards from being used with Medicare, Medicaid, or other government-funded coverage. The $50 bridge copay and the $2,100 annual Part D out-of-pocket cap are the primary cost protections available.
The bridge is a temporary demonstration program running through December 2027. After that, coverage may continue through the BALANCE model or other CMS programs, but permanent statutory coverage requires Congress to change the law. Nothing is guaranteed past 2027.
No. The Extra Help (Low Income Subsidy) program does not apply to bridge program medications. You pay the full $50 regardless of income or subsidy status. This is one of the more counterintuitive aspects of the bridge program.
Find Medicare GLP-1 Clinics by State
Explore More Resources
Find a GLP-1 Clinic That Takes Your Insurance
Search our directory of 2,888 clinics and filter by insurance, medication, and telehealth availability.
Disclaimer: Insurance coverage information is based on publicly available data and may not reflect your specific plan. Coverage, cost, and requirements can change. Always check with your insurer directly before making treatment decisions.